Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
This story comes from CNBC's feed; the full article and all rights belong to the source.
Comments (0)
No comments yet. Be the first to comment.
Sign in to write a comment.